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Abstract. The extent of graft damage after ischemia-reperfu-
sion reflects the balance between deleterious events and pro-
tective factors. Heme oxygenase-1 (HO-1) and vascular endo-
thelial growth factor (VEGF) may contribute to cytoprotection
by their anti-inflammatory and antiapoptotic properties. For
investigating whether HO-1 and VEGF play a role in the
adaptive response to ischemia-reperfusion injury after renal
transplantation, kidney biopsies were analyzed from living (n
 45) and cadaveric (n  16) donors, obtained at three time
points: at the end of cold storage T(1), after warm ischemia
T(0), and after reperfusion T(1). The mRNA expression
levels of HO-1, VEGF165, Bcl-2, Bax, and hypoxia inducible
factor-1 were quantified by real-time reverse transcriptase–
PCR, and the HO-1 and VEGF proteins were analyzed by
immunohistochemistry. Cadaveric donor kidneys presented
higher mRNA expression levels of hypoxia inducible factor-
1. In contrast, mRNA expression levels of HO-1, VEGF165,
and Bcl-2 were significantly lower in kidneys from cadaveric
donors. Overall, a significant correlation was observed be-
tween mRNA expression of Bcl-2 and VEGF165, between
Bcl-2 and HO-1, and between HO-1 and VEGF165. Moreover,
protein expression of HO-1 and VEGF was detected in the
same anatomical kidney compartments (glomerulus, arteries,
and distal tubules). Renal function at the first week posttrans-
plantation (analyzed by serum creatinine levels) showed a
significant correlation with both HO-1 and VEGF mRNA
expression, reinforcing the protective role of both genes in the
early events of transplantation. It is concluded that the lower
expression of HO-1, VEGF165, and Bcl-2 in cadaveric donor
kidneys can reflect a defective adaptation against ischemia-
reperfusion injury that may affect their function in the short
term.
Ischemia-reperfusion injury has been considered as an impor-
tant process occurring in the early phase of organ transplanta-
tion, potentially affecting cell integrity and instigating an in-
flammatory response (1–3). Prolonged cold storage and
reperfusion have been associated with loss of tubular epithelial
cells, significantly contributing to primary failure and delayed
graft function in the immediate period after kidney transplan-
tation (4,5). Moreover, delayed graft function induced by isch-
emia-reperfusion injury may also influence the long-term graft
survival, identified as an important risk factor for chronic
allograft dysfunction (6,7). Theoretically, both the intensity of
the injury and the presence of intrinsic protective properties of
renal tissue may influence the severity of the graft damage. An
appropriate protective response may tip the balance toward a
less hazardous event related to the damage of ischemia-reper-
fusion process.
The heme oxygenase-1 (HO-1) heat shock protein has been
shown to mediate antioxidant, anti-inflammatory, and anti-
apoptotic functions as well as the regulation of vascular tone
(8–10), with a clear cytoprotective effect demonstrated in
several experimental models of organ transplantation (11–13).
In kidney transplant models, overexpression of HO-1, induced
by pharmacologic or heat preconditioning manipulations, pro-
longed graft survival and long-term function after extended
periods of ischemia, reducing apoptosis and the levels of
proinflammatory cytokines (14,15).
Another factor that may play a role in the adaptive graft
response is the vascular endothelial growth factor (VEGF), a
potent angiogenic and endothelial cell-specific mitogen. In
some experimental models of kidney disease, VEGF expres-
sion was crucial to preservation and repair of endothelial
glomerular cells and peritubular capillaries, effectively pre-
venting progressive renal disease (16). In rat liver transplanta-
tion, the addition of VEGF to cultured sinusoidal endothelial
cells attenuated the damage induced by cold preservation,
inhibiting cellular apoptosis (17), which is possibly mediated
by the increased expression of the antiapoptotic proteins such
as A1 and Bcl-2 (18).
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It has been demonstrated that the mRNA expression of HO-1
and VEGF is increased under hypoxia/ischemia conditions, via
the activation of an oxygen-sensing receptor, which ultimately
leads to the induction of the transcription factor hypoxia in-
ducible factor-1 (HIF-1) (19,20). We have recently shown that
renal allografts from cadaveric donors present higher levels of
mRNA expression of HIF-1 when compared with living do-
nors, possibly influenced by extended periods of cold storage
(21).
In the present study, we investigated the participation of
HO-1 and VEGF on the adaptive response to ischemia-reper-
fusion injury by analyzing the mRNA and protein expression
of these two genes in kidney biopsies from living donors (short
ischemia time) and cadaveric donors (prolonged ischemia
time), obtained before and after reperfusion. In addition, to
investigate a possible pathway by which both HO-1 and VEGF
exert their cytoprotective effects and whether they are under
the transcriptional control of HIF-1, we measured mRNA
expression levels of proapoptotic (Bax) and antiapoptotic
(Bcl-2) markers and HIF-1.
Materials and Methods
Patients and Biopsy Material
A total of 183 kidney biopsies were obtained for examination from
45 living donors and 16 cadaveric donors. Biopsies were taken at three
sequential time points: (1) at the end of cold storage (T[1]), (2) after
intraoperative warm ischemia (T[0]), and (3) 30 min after reperfusion
(T[1]).
Kidneys from living donors were retrieved by laparoscopic ne-
phrectomy (n  35) or by conventional nephrectomy (n  10) and
preserved with Euro-Collins solution. Cadaveric donor kidneys were
procured from nine heart-beating (HB) donors and seven non–heart-
beating (NHB) donors and preserved with UW solution.
Recipient serum creatinine (mol/L) was used to assess graft
function at the end of the first week after transplantation. Morning
creatinine values on day 7 were used for all patients except those on
dialysis, in which case predialysis values on day 6 were used.
Total RNA Extraction
The kidney biopsies were embedded in 500 l of lysis buffer
(Nuclisens; Biomerieux, Boxtel, The Netherlands) and stored at
80°C until used for RNA extraction. Total RNA was isolated from
biopsies using a modification of the method described by Chomczyn-
ski and Sacchi (22). Frozen biopsy fragments, previously embedded in
lysis buffer, were homogenized with 2-mercaptoethanol (Bio-Rad
Laboratories, Hercules, CA) and 20 g/ml poly A (Roche Applied
Science, Almere, The Netherlands). The solution was extracted once
with 700 l of phenol-chloroform-isoamylalcohol (125:49:1),
once with 600 l of phenol-chloroform-isoamylalcohol (50:49:1),
and once with 600 l of chloroform-isoamylalcohol (49:1). Subse-
quently, total RNA was precipitated with 600 l of 2-propanol and 35
l of 3M sodium acetate (pH 5.2) at 20°C. After 18 h, precipitates
were pelleted at 10,000  g at 4°C during 20 min and washed once
with 500 l of ice-cold 80% ethanol. Pellets were air dried and
resuspended in 50 l of diethylpyrocarbonate-treated (Sigma-Aldrich
Chemie, Steinheim, Germany) water.
cDNA Synthesis
Total RNA was denatured for 5 min at 80°C and then chilled on ice.
First-strand cDNA synthesis was performed from the isolated RNA at
42°C for 90 min in a volume of 50 l. The reaction mixture contained
10 l of 5 first-strand buffer (Life Technologies-BRL, Gaithers-
burg, MD), 25 pmol of each dNTP (Amersham Pharmacia Biotech
Benelux, Roosendaal, The Netherlands), 0.25 g of random primers
(Promega, Madison, WI), 500 U of M-MLV reverse transcriptase
(Life Technologies-BRL), 20 U of RNAse inhibitor (RNAsin; Pro-
mega), and 0.5 nM of dithiothreitol (Life Technologies-BRL). After
the cDNA reaction, the M-MLV reverse transcriptase was inactivated
by a 5-min incubation at 95°C.
Real-Time PCR
The mRNA levels of HO-1, VEGF165, HIF-1, HIF-1736, Bcl-2,
Bax. and the housekeeping gene 18S (rRNA) were quantified in the
kidney biopsies using real-time PCR in the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA). We used
primer express software (Applied Biosystems) to select sequence-
specific primers and probes for HO-1, VEGF165, HIF-1, and HIF-
1736. HO-1 sense primer, 5'-TGCTCAACATCCAGCTCTTTGA-3',
HO-1 antisense primer, 5'-GCAGAATCTTGCACTTTGTTGCT-3',
and HO-1 probe, FAM-5'-AGTTGCAGGAGCTGCTGACCCAT-
GAC-3'; VEGF165 sense primer, 5'-GCAGACCAAAGAAAGATA-
GAGCAAG-3', VEGF165 antisense primer, 5'-CGCCTCGGCTTGT-
CACAT-3', and VEGF165 probe, FAM-5'-AGAAAATCCCTG
TGGGCCTTGCTCA-3'; HIF-1 sense primer, 5'-AACATGATGGT-
TCACTTTTTCAAGC-3', HIF-1 antisense primer, 5'-GTCAGCT-
GTGGTAATCCACTTTCAT-3', and HIF-1 probe, FAM-5'-TAG-
GAATTGGAACATTATTACAGCAGCCAGACG-3'; HIF-1736
sense primer, 5'-ACTTTTTCAAGCAGTAGGAATTATTTAGC-3',
HIF-1736 antisense primer, 5'-GTCAGCTGTGGTAATCCACTT-
TCAT-3', and HIF-1736 probe, TET-5'-TGTAGACTGCTGGGG
CAATCAATG-3'. Primer sets and FRET probes (Biosource Interna-
tional, Camarillo, CA) were used for Bcl-2 and Bax. Predeveloped
TaqMan assays (Applied Biosystems) were used for 18S. Five micro-
liters of cDNA was added to 45 l of PCR mixture containing 25 l
of Universal PCR Master Mix (Applied Biosystems), 50 pmol of
sense primer, 50 pmol of antisense primer, and 10 pmol of probe for
the in-house developed PCR. Amounts of primers and probes of the
predeveloped kits were added according to the manufacturer’s instruc-
tions. PCR conditions were incubation for 2 min at 50°C, which
enables uracil N'-glycosylase (present in master mix) to inactivate
possible contaminating amplicons, incubation for 10 min at 95°C to
activate AmpliTaq Gold polymerase, followed by 40 cycles of 15-s
denaturation at 95°C, 1 min annealing, and extension at optimal
temperatures (HO-1, HIF-1, HIF-1736, and VEGF165, 59°C; Bcl-2,
Bax, and 18S, 60°C). Standard curves with serial dilutions of known
amounts of the target molecules were used to determine the mRNA
concentrations in biopsies. The measured mRNA concentrations for
the different molecules were standardized for the 18S concentration.
The results were expressed in a ratio between the mRNA concentra-
tion of the target molecule and the mRNA concentration of 18S,
multiplied by 106 because of the lower concentration of the target
gene when compared with the concentration of 18S. A total of 27
biopsy samples (from 22 cases), in which the 18S concentration was
below 100,000 pg/ml, were considered as insufficient material and
subsequently excluded.
Immunohistochemistry
The expression of HO-1 and VEGF-A was studied by immunohis-
tochemistry in kidney biopsies from seven living donors and six
cadaveric donors. These specimens were obtained at time point T0
(after intraoperative warm ischemia).
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Intragraft expression of HO-1 and VEGF-A was performed using a
rabbit polyclonal anti-human HO-1 (Stressgen, Victoria, Canada) and
a rabbit polyclonal anti-human VEGF-A (Clone A-20; Santa Cruz
Biotechnology, Santa Cruz, CA) that reacts with the 165–, 189–, and
121–amino acid splice variants. Optimal working dilutions of the
primary antibodies were previously determined by titration experi-
ments. Negative control experiments for both antigens were per-
formed by omitting the incubation with the primary antibody. In brief,
frozen specimens were cut into 5-m cryostat sections, air-dried, and
fixed in acetone. After blocking endogenous peroxidase activity with
0.3% hydrogen peroxidase, sections were incubated with the primary
antibody for 30 min at room temperature (VEGF) or overnight at 4°C
(HO-1). After rinsing, tissue sections were incubated with goat anti-
rabbit IgG for 30 min at room temperature, followed by incubation
with PAP complex. Peroxidase activity was visualized using diami-
nobenzidine solution. The immunohistochemistry results were evalu-
ated blindly by two independent investigators.
Statistical Analyses
All data are presented as median. The comparison of mRNA
expression levels between living and cadaveric donors, at each time
point, was evaluated by unpaired Mann-Whitney U test. Repeated
measures nonparametric test (Friedman’s test) was used for compar-
ison of mRNA expression levels among the three time points. After
logarithmic transformation, the relationships between variables were
assessed by Pearson correlation and univariate linear regression anal-
ysis. All tests were two-tailed, and P  0.05 was considered
significant.
Results
Patient Characteristics
The median ages of living and cadaveric donors were 50 yr
(range, 27 to 74 yr) and 46 yr (range, 29 to 58 yr), respectively
(P  0.07), with predominance of female donors (62 and 52%,
respectively). The period of intraoperative warm ischemia was
similar among living donors (26 min; range, 15 to 90 min), HB
cadaveric donors (27 min; range, 20 to 67 min), and NHB
cadaveric donors (27 min; range, 18 to 45 min; P  0.31). In
living donors, the time of cold ischemia was aimed to be lower
than 2 h in all cases. Cold ischemia time was 19 h (14 to 32 h)
among HB donors and 27 h (15 to 30 h) among NHB donors
(P  0.30).
The majority of the recipients were men (66%) and received
their first allograft (82%). The median ages were 47 yr (range,
20 to 74 yr).
Higher mRNA Expression of HIF-1 in
Cadaveric Donors
The mRNA expression of HIF-1FL after cold ischemia
T(1) and intraoperative warm ischemia T(0) was signifi-
cantly higher in cadaveric donor kidneys than in living donor
kidneys (Figure 1), which is in line with our previous findings
(21). Accordingly, mRNA expression of HIF-1736 was also
observed to be higher in cadaveric than living donor kidneys in
all studied time points (Figure 1).
Lower mRNA Expression of HO-1 and VEGF165 in
Cadaveric Donor Kidneys
The mRNA expression levels of HO-1 and VEGF165 were
significantly lower in kidneys from cadaveric donors when
compared with living donors (Figure 2). In all three time
points, HO-1 mRNA expression was approximately 3.5 times
lower in cadaveric donors. Similarly, VEGF165 mRNA expres-
sion was at least fivefold lower in kidney biopsies from ca-
daveric donors in all time points.
The comparison between living donor kidneys retrieved by
laparoscopic nephrectomy and by open nephrectomy showed
no difference in either the median levels of HO-1 mRNA
expression (T[1]: lap  1096 versus open  983; T[0]: lap
 755 versus open 1802; T[1]: lap 1468 versus open
1161, NS for all time points) or the median levels of VEGF165
mRNA expression (T[1]: lap  64.6 versus open  42.9;
T[0]: lap  39.2 versus open  116.1; T[1]: lap  71.7
Figure 1. mRNA expression levels of hypoxia inducible factor (HIF)-1FL (A) and its isoform HIF-1736 (B) in kidney biopsies from living
and cadaveric donors. Biopsies were taken at three time points: after cold ischemia (T[1]), after intraoperative warm ischemia (T[0]), and after
reperfusion (T[1]). The mRNA expression levels were normalized to 18S rRNA concentrations and multiplied by a factor 106. The median
levels are represented in each group, and P value is the result of the comparison between living and cadaveric donor kidneys, at each time point
(Mann-Whitney test).
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versus open  54.9; NS for all time points). The comparison
between cadaveric kidneys procured from HB donors and from
NHB donors was not different in the median levels of HO-1
mRNA expression (T[1]: HB  302 versus NHB  249;
T[0]: HB 263 versus NHB 250; T[1]: HB 240 versus
NHB  332; NS for all time points) and in the median levels
of VEGF165 mRNA expression (T[1]: HB 9.9 versus NHB
 10.5; T[0]: HB  8.5 versus NHB  7.2; T[1]: HB  4.0
versus NHB  8.5; NS for all time points).
Relationship between mRNA Expression of HO-1
and VEGF165
A highly significant correlation was observed between
mRNA expression levels of VEGF165 and of HO-1 at T(1) (r
 0.594, P  0.0001), T(0) (r  0.808, P  0.0001), and
T(1) (r  0.771, P  0.0001; Figure 3).
Renal Expression of HO-1 and VEGF Protein
The expression of HO-1 and VEGF protein in living and
cadaver donor kidneys was detected within the glomeruli,
tubular epithelial cells, and renal arteries (Figure 4). Glomer-
ulus showed diffuse staining for both HO-1 and VEGF. There
was a marked expression of HO-1 and VEGF protein in arteries
and arterioles, prominently in the muscular layers. In tubules,
both HO-1 and VEGF were detected in a subset of narrow
cortical tubules with morphologic characteristics of the distal
convoluted tubules.
A weak HO-1 staining was observed in glomeruli and ar-
Figure 2. Heme oxygenase-1 (HO-1; A) and vascular endothelial growth factor (VEGF165; B) mRNA expression levels in kidney biopsies from
living and cadaveric donors. Biopsies were taken at three time points: after cold ischemia (T[1]), after intraoperative warm ischemia (T[0]),
and after reperfusion (T[1]). The mRNA expression levels were normalized to 18S rRNA concentrations and multiplied by a factor 106. The
median levels are represented in each group, and P value is the result of the comparison between living and cadaveric donor kidneys, at each
time point (Mann-Whitney test).
Figure 3. Correlation between HO-1 and VEGF165 mRNA expression levels in kidney biopsies from living and cadaveric donors, obtained after
cold ischemia (n  52; A), after intraoperative warm ischemia (n  50; B) and, after reperfusion (n  49; C).
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Figure 4. Immunohistochemical staining for HO-1 and VEGF-A in kidneys from living donors. Negative controls stained omitting primary
antibody (A and B). Diffuse glomerular expression of HO-1 (C) and VEGF (D). Marked expression of HO-1 (E) and VEGF (F) in arteries and
arterioles. HO-1 (G) and VEGF (H) expression in distal convoluted tubules. Magnification, 400.
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teries from two of six kidney biopsies from cadaveric donors
(Figure 5). The intensity of VEGF staining was comparable in
tubules and arteries from living and cadaveric donor kidneys
but less intense in glomeruli from four of six cadaveric donor
kidneys.
Lower mRNA Expression of Bcl-2 in Cadaveric Donor
Kidneys
Living and cadaveric donor kidneys expressed similar pro-
apoptotic Bax mRNA expression levels in all studied time
points (Figure 6). In contrast, the mRNA expression levels of
the antiapoptotic molecule Bcl-2 was significantly lower in
kidneys from cadaveric donors, when compared with kidneys
from living donors (Figure 6). As a consequence, the Bcl-2/Bax
ratio was significantly reduced in cadaveric donor kidneys.
Relationship between mRNA Expression of HO-1/
VEGF165 and Bcl-2
A significant correlation was observed between mRNA ex-
pression levels of VEGF165 and Bcl-2 in all time points (all
biopsies taken together), at T(1) (r  0.770, P  0.0001),
T(0) (r  0.640, P  0.0001) and T(1) (r  0.7096, P 
0.0001; Figure 7). Also, a significant correlation was observed
between HO-1 and Bcl-2 mRNA expression levels in all time
points (T[1]: r  0.278, P  0.046; T[0]: r  0.335, P 
0.018; T[1]: r  0.449, P  0.0001).
mRNA Intragraft Expression after Cold Ischemia,
Warm Ischemia, and Reperfusion
Sequential kidney biopsies at all three time points were
available for a total of 30 living and nine cadaveric donors. In
these cases, the levels of mRNA expression were quantitatively
compared among the three time points. No difference was
observed in the quantitative levels of HO-1, VEGF165, Bcl-2,
Bax, HIF-1FL, and HIF-1736 mRNA expression across all
time points, regardless of donor type (NS for all, Friedman’s
test).
Graft Function and mRNA Intragraft Expression
The mean serum creatinine at the first week after transplan-
tation was 223 mol/L (range, 81 to 875 mol/L) in patients
who had received a living kidney graft and 930 mol/L (range,
109 to 1965 mol/L) in patients who had received a cadaveric
kidney graft (P  0.001). The serum creatinine was higher in
recipients of NHB donors (1318 mol/L; range, 726 to 1965)
compared with recipients of HB donors (629 mol/L; range,
109 to 1546; P  0.04). Delayed graft function, defined as the
requirement for dialysis in the first week after transplantation,
was more frequently observed in cadaver recipients (11 of 16)
than in living recipients (4 of 45; P  0.0001). A significant
inverse correlation was noted between serum creatinine levels
at the first week after transplantation and mRNA expression
level of HO-1 (n  50) and VEGF165 (n  49) after reperfu-
sion (HO-1: r  0.44, P  0.001; VEGF165: r  0.41,
P  0.003).
Discussion
In the present study, the expression of cytoprotective genes
was investigated in living and cadaveric donor kidneys during
cold and warm ischemia and after reperfusion. As compared
with living donor grafts, cadaveric organs presented an evident
lower mRNA expression of HO-1, VEGF165, and Bcl-2 across
all studied time points. Moreover, mRNA expression levels of
HO-1 and VEGF165 after reperfusion significantly correlated
with the renal function in the first week after transplantation.
The lower levels of HO-1 and VEGF165 mRNA expression
observed in cadaveric donor kidneys may represent a defective
response against ischemia-reperfusion injury. These two fac-
tors have been previously documented to have cytoprotective
properties that may contribute to counterbalance the damage
Figure 5. Immunohistochemical staining for HO-1 in kidneys from cadaveric donors. HO-1 staining was weak in glomerulus (A) and artery
(B) of two of six cadaveric donor kidneys. Magnification, 400.
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induced by ischemia-reperfusion (11–13,17). By-products of
heme oxygenase have antioxidant, anti-inflammatory, and an-
tiapoptotic activities, contributing to prolong graft survival in
experimental models of kidney transplant (14,15). VEGF, in
turn, is a proangiogenic factor implicated as an important
survival factor for endothelial glomerular cells and peritubular
capillaries (16).
Sequential kidney biopsies were collected to investigate
whether gene expression could differ among distinct phases of
ischemia-reperfusion, but no difference was observed in the
mRNA levels of all factors across the three time points, re-
gardless of donor type. In healthy, euvolemic, elective, living
donors, the mRNA levels of HO-1 and VEGF165 measured
after a short period of cold ischemia probably reflect the basal
constitutive expression of these factors. Moreover, no differ-
ences were observed in the expression of these genes between
laparoscopic and conventional nephrectomy in living donors.
The first kidney biopsy of cadaveric donors was obtained at the
end of the cold storage, which ranged from 14 to 32 h. Because
of logistical reasons related to the official organ retrieval
process, no biopsy could be obtained at the moment of kidney
harvesting, immediately before cold preservation. In this re-
gard, we cannot rule out that early overexpression of HO-1 and
VEGF165 mRNA in cadaveric donors could have occurred
before retrieval, followed by a drop in mRNA expression
throughout the cold ischemic period. However, previous stud-
ies have indicated that a major change in the gene expression
during cold preservation is unlikely to occur, probably induced
by a steady state in the activity of RNA polymerases necessary
for gene transcription (3). In the present study, there were no
Figure 6. mRNA expression levels of antiapoptotic Bcl-2 (A) and proapoptotic Bax (B) in kidney biopsies from living and cadaveric donors
obtained after cold ischemia (T[1]), intraoperative warm ischemia (T[0]), and reperfusion (T[1]). The mRNA expression levels were
normalized to 18S rRNA concentrations and multiplied by a factor 106. The ratio between Bcl-2 and Bax mRNA expression levels (C) was
significantly lower in cadaveric than in living donor kidneys (Mann-Whitney test).
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changes in the mRNA levels of HO-1, VEGF165, Bcl-2, Bax,
and HIF-1 after 30 min of reperfusion. However, whether
further changes would occur at a later stage (e.g., at 1 h) still
remains to be clarified.
Organs retrieved from living and cadaveric donors markedly
differ as a result of several pathophysiologic events that may
occur before the procurement of cadaver organs. Apart from
medical comorbidities commonly found in these individuals
(e.g., cardiovascular instability), the presence of established
brain death has been documented to alter significantly the
inflammatory systemic profile (23). It is possible, therefore,
that specific conditions related to cadaveric-donor organs could
alternatively trigger the release of soluble factors, which may
ultimately decrease the mRNA expression of HO-1 and
VEGF165 as observed in our study. Macrophage-derived cyto-
kines have been shown to inhibit VEGF mRNA expression and
protein secretion in cultured tubular cells of animals with
kidney interstitial fibrosis, under both normoxia and hypoxia
(16). In vitro studies with human cells have also shown a
decrease in the HO-1 mRNA and protein expression by inter-
feron- (24,25).
It is worth noting that the gene expression of HO-1 and
VEGF165 was significantly correlated in our study. It can be
speculated that gene transcription of HO-1 and VEGF165 is
controlled by the same transcription factor. In this context, we
have evaluated the expression of HIF-1, a transcription factor
previously implicated as a possible controller of the HO-1 and
VEGF gene transcription in hypoxic conditions (19,20). Nev-
ertheless, no relation was observed between the levels of
HIF-1 and HO-1 or VEGF165 expression. The high levels of
HIF-1 and HIF-1736 detected in cadaveric donor kidneys
were associated with low levels of mRNA encoding HO-1 and
VEGF165, suggesting that the transcription of these genes is not
under the main control of HIF-1. Contrary to our expecta-
tions, these low levels of HO-1 and VEGF165 in cadaveric
grafts contrast to their higher hypoxic exposure, as reflected by
the high expression of HIF-1. However, human cell lines
were demonstrated recently to present decreased expression
levels of HO-1 under hypoxia, with protein Bach-1 being
implicated as a hypoxia-inducible repressor for the HO-1 gene
(25). In addition, a peculiar response to experimental hypoxia
has been demonstrated in the kidney, which may redistribute
the pre-existing VEGF protein, rather than increase mRNA and
protein synthesis (26).
Apart from the correlation between HO-1 and VEGF gene
expression, protein expression of HO-1 and VEGF was de-
tected in the same sites within the kidney, suggesting that the
two proteins are potentially involved in the cytoprotection of
similar anatomic compartments. Although the glomerular ex-
pression of VEGF has been previously described in normal
human kidneys (27), conflicting findings have been reported
regarding the glomerular production of HO-1, being detected
in transplanted patients with acute rejection (28) but not in
patients with glomerulopathies (29). In our series, HO-1 and
VEGF staining were less intense in some kidney biopsies from
cadaveric donors, suggesting that the protein expression may
also be altered in cadaveric donor kidneys during
ischemia-reperfusion.
We found a marked difference between living and cadaveric
donor kidneys regarding the balance between antiapoptotic
(Bcl-2) and proapoptotic (Bax) genes. Cadaveric donor kid-
neys presented decreased Bcl-2/Bax ratio as a consequence of
reduced levels of Bcl-2 mRNA expression. This impaired
expression of Bcl-2 in cadaveric donor kidneys can increase
the susceptibility to apoptosis and thus contribute to delayed
graft function after transplantation (30). It has been shown that
upregulation of Bcl-2 is a possible pathway through which
HO-1 and VEGF exert their cytoprotective effects (13,31). In
fact, VEGF may trigger Bcl-2 production, which can, in turn,
mediate the survival activity of VEGF (18). It is interesting that
we observed a significant correlation between the mRNA ex-
pression levels of Bcl-2 and VEGF165 and between Bcl-2 and
HO-1, suggesting a direct interaction among these three pro-
tective genes.
Figure 7. Correlation between mRNA expression levels of Bcl-2 and VEGF165 in all kidney biopsies from living and cadaveric donors, obtained
after cold ischemia (n  52; A), after intraoperative warm ischemia (n  50; B), and after reperfusion (n  49; C).
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In the present study, a significant association was observed
between renal function in the first posttransplantation week and
the levels of HO-1/VEGF mRNA expression, highlighting the
clinical relevance of the protective effect of these two genes in
the early outcomes after kidney transplantation. Furthermore,
the lower expression of protective genes in cadaveric donor
kidneys may represent a defective adaptation against ischemia-
reperfusion, interfering in the short-term clinical outcome. One
can speculate on the possibility to induce overexpression of
these genes in clinical practice to improve postoperative kidney
allograft function.
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